Results 121 to 130 of about 72,887 (326)

Comparing Poly (ADP–Ribose) Polymerase Inhibitors With Standard Chemotherapy in BRCA-Mutated, Recurrent Ovarian Cancer: Lessons Learned From a Negative Trial [PDF]

, 2011
Panagiotis A. Konstantinopoulos, Stephen A. Cannistra   +1 more
openalex   +1 more source

A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. [PDF]

, 2015
BACKGROUND: Personalized therapy considering clinical and genetic patient characteristics will further improve breast cancer survival. Two widely used treatments, chemotherapy and radiotherapy, can induce oxidative DNA damage and, if not repaired, cell ...
Aittomäki, Kristiina, Alnæs, Grethe G, Behrens, Sabine, Blomqvist, Carl, Bolla, Manjeet K., Børresen-Dale, Anne-Lise, Chang-Claude, Jenny, Couch, Fergus J., Dunning, Alison M., Easton, Doug F, Fagerholm, Rainer, Flesch-Janys, Dieter, Hall, Per, Hamann, Ute, Hartikainen, Jaana M., Hollestelle, Antoinette, Hooning, Maartje J, Humphreys, Keith, Jager, Agnes, Kabisch, Maria, Kataja, Vesa, Kosma, Veli-Matti, Kristensen, Vessela, Lambrechts, Diether, Li, Jingmei, Liu, Jianjun, Mannermaa, Arto, Margolin, Sara, Michailidou, Kyriaki, Nevanlinna, Heli, Nord, Silje, Pharoah, Paul, Popanda, Odilia, Purrington, Kristen S, Rhenius, Valerie, Schildkraut, Joellen M, Schmezer, Peter, Schmidt, Marjanka K., Seibold, Petra, Seynaeve, Caroline, Shah, Mitul, Torres, Diana, Ulmer, Hans-Ulrich, Wang, Qin, Wildiers, Hans   +44 more
core   +4 more sources

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer

The Journal of Clinical Pharmacology, EarlyView.
Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene‐mutated metastatic castration‐resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe.
Mark Hadigol, Jason H. Williams, Haihong Shi, Derek Z. Yang, Justin Hoffman, Diane D. Wang   +5 more
wiley   +1 more source

Protocol for quantifying PARP inhibitor-induced changes in PARP1 dynamics and activity through live-cell imaging

STAR Protocols
Summary: Poly(ADP-ribose) polymerase 1 (PARP1) is a crucial DNA repair protein and a target of PARP inhibitors (PARPi), which suppress its catalytic activity while also altering its association with damaged chromatin. Here, we present a live-cell imaging
Petar-Bogomil Kanev, Sylvia Varhoshkova, Aleksander Aleksandrov, Stoyno Stoynov, Radoslav Aleksandrov   +4 more
doaj   +1 more source

Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors [PDF]

, 2019
Yunjiang Zhou, Shi Tang, Tingting Chen, Miaomiao Niu   +3 more
openalex   +1 more source

CRISPR Enabled Precision Oncology: From Gene Editing to Tumor Microenvironment Remodeling

Med Research, EarlyView.
CRISPR technology has progressed from a prokaryotic immune system to a diverse suite of editing platforms, including Cas nucleases, base and prime editors, and RNA‐targeting enzymes. These advances enable precise genomic and epigenomic interventions, high‐throughput functional screening, and immune engineering.
Kailai Li, Peixin Huang, Yue Qian, Anqi Lin, Jingjun He, Junyi Shen, Li Chen, Kai Miao, Jian Zhang   +8 more
wiley   +1 more source

Supplementary Figure 1 from Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase <i>In Vitro</i> [PDF]

, 2023
Anand G. Patel, Silvana B. De Lorenzo, Karen S. Flatten, Guy G. Poirier, Scott H. Kaufmann   +4 more
openalex   +1 more source

Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure [PDF]

, 2006
Overactivation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) contributes to the development of cell dysfunction and tissue injury in various pathophysiological conditions associated with oxidative and nitrosative stress, including myocardial ...
Cziraki, A., Hasko, G., Liaudet, L., Mabley, J. G., Pacher, P., Szabo, C.   +5 more
core   +1 more source

Nuclear Alpha‐Synuclein: Mechanisms and Implications for Synucleinopathies

Movement Disorders, EarlyView.
Abstract Alpha‐synuclein (aSyn), historically studied for its synaptic functions and central role in Lewy body pathology, is emerging as a protein with significant nuclear activities relevant to Parkinson's disease (PD) and related synucleinopathies. Recent advances reveal that aSyn dynamically localizes to neuronal nuclei in both health and disease ...
Tiago Fleming Outeiro, David J. Koss
wiley   +1 more source

Mapping genetic interactions in cancer: a road to rational combination therapies. [PDF]

, 2019
The discovery of synthetic lethal interactions between poly (ADP-ribose) polymerase (PARP) inhibitors and BRCA genes, which are involved in homologous recombination, led to the approval of PARP inhibition as a monotherapy for patients with BRCA1/2 ...
Krogan, Nevan J, Tutuncuoglu, Beril
core